Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with…. Sold as Cyramza. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Ramucirumab (sold as Cyramza), first approved Apr 21, 2014, with 7 new uses approved and 0 published complete response letters.
First approved: Apr 21, 2014
Applications: 1
New uses approved: 7
Complete response letters: 0
Medicare spending, 2025: $146M
First approved in the EU: Dec 19, 2014
First approved in Japan: Mar 26, 2015
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 11 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
CyramzaDrugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. · Eli Lilly Japan K.K. · Nov 27, 2020
CyramzaDrugs with a new indication for the treatment of patients with unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and… · Eli Lilly Japan K.K. · Jun 18, 2019
CyramzaDrugs with a new additional indication and a new dosage for the treatment of unresectable advanced/relapsed non-small cell lung cancer. · Eli Lilly Japan K.K. · Jun 20, 2016 · Review report
CyramzaDrugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent colorectal cancer. · Eli Lilly Japan K.K. · May 23, 2016 · Review report
Cyramza, new ingredientDrugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent gastric cancer. · Eli Lilly Japan K.K. · Mar 26, 2015 · Review report
Clinical Trials
55 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA